Commodity Channel Index
|Bid||17.19 x 1000|
|Ask||23.04 x 800|
|Day's Range||16.21 - 17.32|
|52 Week Range||9.40 - 30.86|
|Beta (5Y Monthly)||2.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The results will be presented by Dr. Angela Tatiana Alistar, M.D., Medical Director of Gastrointestinal (GI) Medical Oncology at Morristown Medical Center and principal investigator on the trial. Overall, the treatment was well-tolerated and demonstrated positive results that show devimistat can be safely administered with gemcitabine and nab-paclitaxel at doses up to 1,500 m/g2.
The Barer Institute Inc. a subsidiary of Rafael Holdings, Inc. (NYSE: RFL) and University Place Associates (UPA) have announced that The Barer Institute has signed a non-binding Letter of Intent to lease Growth Pod space at 3.0 University Place in University City.
“With generally poor responses to current therapies and a five-year survival rate of just 28%, there are significant gaps in treatments for adult AML patients,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. Should these experiments show efficacy of devimistat additional AML trials in the upfront setting will be considered.
Through this collaboration, researchers will evaluate the effects of CPI-613® (devimistat) with or without chemotherapy agents, including oxaliplatin/cisplatin/5-FU/carboplatin/taxol, on esophageal cancer cells. “With our focus on hard-to-treat cancers, especially those in the gastrointestinal tract, research in treating esophageal cancer has been a significant goal for us,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “The high standards and caliber of researchers at Roswell Park made this research possible, and we are honored to partner with them.”
The clinical trial will begin enrolling patients at MD Anderson Cancer Center, where Dr. Raphael Steiner will serve as principal investigator. The trial is led by Ariela Noy, M.D., at Memorial Sloan Kettering Cancer Center in New York City. “We are happy to expand access to our clinical trial for patients with Burkitt’s lymphoma, especially through the highly prestigious institution of MD Anderson, alongside the other world-renowned sites for this trial,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Cranbury, NJ, April 23, 2020 -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced.
“We are continuing to enroll patients ahead of schedule, as the patients in our trials suffer from life-threatening diseases and are in dire need of treatment; patient safety is our top priority,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “To Save a Life is to Save a Universe” – Rafael’s motto – represents its dedication to patients who suffer from rare cancers globally, as well as to its employees and the communities it serves.
Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per diluted share of $0.08 for the fiscal quarter ended January 31, 2020.
Cranbury, NJ, March 03, 2020 -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today.
There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But if when you choose...
LipoMedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announced that Phase 1 data of Promitil® (PL-MLP) in patients with metastatic colorectal cancer (CRC) was published in the research journal Investigational New Drugs. Prolonged survival of stable disease patients was also observed, with a median survival of 14.4 months, significantly longer than of progressive disease patients (6.5 months) and non-evaluable patients (2.3 months).
The study will be a multicenter randomized trial of gemcitabine and cisplatin with or without devimistat as a first-line therapy for patients with locally advanced, unresectable or metastatic biliary tract cancer who have had no prior treatment. The goal of the Phase 1b part of the trial will be to identify the maximum tolerated dose (MTD), or the highest dose of devimistat that does not cause side effects, when given in combination with gemcitabine and cisplatin.
Cranbury, NJ, Jan. 14, 2020 -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced.
The Barer Institute, a collaborative cancer drug development initiative of Rafael Holdings, Inc., (NYSE: RFL), today announced the slate of highly regarded scientific and business leaders that will serve as its founding Board of Directors.
Mr. Luther will discuss the status of the Company’s clinical development strategy, as well as provide an update on the drug development pipeline and its plans for new trials in 2020. Rafael is currently conducting two pivotal Phase 3 clinical trials for its drug CPI-613® (devimistat) in patients with metastatic pancreatic cancer and acute myeloid leukemia (AML).
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Rafael Holdings, Inc., (NYSE: RFL), has launched an initiative to identify and develop or in-license promising pre-clinical compounds targeting the unique cellular metabolism of cancers with high levels of unmet needs.
Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.10 for the fiscal quarter ended October 31, 2019.
Cranbury, NJ, Dec. 03, 2019 -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today.
Dr. Pardee will present the study design and method of testing the efficacy of devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone alone for older patients (≥60 years of age) with relapsed or refractory AML in Rafael’s Phase 3 clinical trial.
The clinical trial will begin enrolling patients at Massachusetts General Hospital in Boston starting this month. The trial is currently underway at Memorial Sloan Kettering Cancer Center in New York City and at City of Hope in Duarte, California. “Burkitt’s lymphoma is a rare disease, with approximately 1,200 people in the United States diagnosed annually, so treatment options for these patients are very limited,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.
NEWARK, N.J., Nov. 18, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), announced today that it has been approved for listing on the New York Stock Exchange (NYSE). The Company anticipates that its Class B common stock will begin trading on the NYSE on November 21, 2019 with its current ticker symbol (RFL). The stock will continue trading on the NYSE American through the close of trading on November 20, 2019.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]